Brooks Laboratories News

Brooks Laboratories Gets Credit Rating Upgrade from CARE Ratings

Brooks Laboratories Limited received a credit rating upgrade from CARE Ratings Limited. The long-term bank facilities rating was upgraded to CARE BB+ Stable from CARE BB- Stable, while the short-term bank facilities rating of CARE A4 was reaffirmed. The upgrade reflects expected improvement in financial performance in FY26 with projected total operating income of ₹100 crore and higher profit margins driven by lower purchase costs due to stronger supplier negotiations. The company reported total operating income of ₹83.04 crore in FY25 with PBILDT and PAT margins of 6.03% and 3.68% respectively. CARE Ratings noted the announced merger of Brooks Laboratories' associate company Brooks Steriscience Limited into OneSource Speciality Pharma Limited, expected to be completed by December 2026. Brooks Laboratories will receive a 1.50% equity stake in OneSource Speciality Pharma in lieu of its 49% stake in Brooks Steriscience Limited. The merger is expected to enhance liquidity position and discontinue the corporate guarantee of ₹68.62 crore extended for Brooks Steriscience Limited's borrowings.

Brooks Steriscience Approves Multi-Entity Merger Scheme Involving OneSource Specialty Pharma

Brooks Steriscience Limited's board has approved a composite scheme involving mergers between five pharmaceutical entities: Steriscience Specialties, Brooks Steriscience, Steriscience Pte, Strides Pharma Services, and OneSource Specialty Pharma. The scheme consolidates sterile injectable manufacturing operations under OneSource through multiple amalgamations. Key financial metrics show OneSource with the largest turnover at INR 12,995.89 million and net worth of INR 59,108.37 million. The merger uses share exchange ratios rather than cash consideration - 48 Brooks Steriscience shares for every 10 Steriscience Specialties shares, and 137 OneSource shares for every 10 Brooks Steriscience shares. Post-merger, OneSource's promoter shareholding will increase from 29.77% to 36.17%. The scheme requires approvals from shareholders, creditors, stock exchanges, SEBI, National Company Law Tribunal, Singapore High Court, and other regulatory authorities. The consolidation aims to strengthen business capabilities, create operational synergies, and enhance shareholder value in the contract development and manufacturing operations sector.